UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC

Lung cancer (Amsterdam, Netherlands), 2019-01, Vol.127, p.153-163

2019

Volltextzugriff (PDF)

Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect

Journal of thoracic oncology, 2019-07, Vol.14 (7), p.e145-e146

2019

Volltextzugriff (PDF)

Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2018-12, Vol.126, p.9-14

2018

Volltextzugriff (PDF)

Current Status of Second-Line Treatment and Novel Therapies for Small Cell Lung Cancer

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.764-772

2007

Volltextzugriff (PDF)

Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer

Journal of thoracic oncology, 2011-03, Vol.6 (3), p.489-493

2011

Volltextzugriff (PDF)

Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients

Lung cancer (Amsterdam, Netherlands), 2014-12, Vol.86 (3), p.324-328

2014

Volltextzugriff (PDF)

Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence

Therapeutic Advances in Respiratory Disease, 2017-09, Vol.11 (9), p.353-373

2017

Volltextzugriff (PDF)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors

JTO clinical and research reports, 2023-09, Vol.4 (9), p.100563-100563, Article 100563

2023

Volltextzugriff (PDF)

Thoracic myopericytoma in an older adult, rare but possible: A case report

Thoracic cancer, 2022-09, Vol.13 (17), p.2532-2535

2022

Volltextzugriff (PDF)

ALK Rearrangement Testing by FISH Analysis in Non–Small-Cell Lung Cancer Patients: Results of the First Italian External Quality Assurance Scheme

Journal of thoracic oncology, 2014-10, Vol.9 (10), p.1470-1476

2014

Volltextzugriff (PDF)

Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis

JTO clinical and research reports, 2021-09, Vol.2 (9), p.100214-100214, Article 100214

2021

Volltextzugriff (PDF)

Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database

Lung cancer (Amsterdam, Netherlands), 2021-11, Vol.161, p.18-25

2021

Volltextzugriff (PDF)

ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data

Lung cancer (Amsterdam, Netherlands), 2020-07, Vol.145, p.95-104

2020

Volltextzugriff (PDF)

Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2013-04, Vol.80 (1), p.35-38

2013

Volltextzugriff (PDF)

Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical Issue

Journal of thoracic oncology, 2023-10, Vol.18 (10), p.e112-e113

2023

Volltextzugriff (PDF)

Second-Line Treatment of Advanced Non-small Cell Lung Cancer

Journal of thoracic oncology, 2008-04, Vol.3 (4), p.430-440

2008

Volltextzugriff (PDF)

Comparison Between Epidermal Growth Factor Receptor (EGFR) Gene Expression in Primary Non-small Cell Lung Cancer (NSCLC) and in Fine-Needle Aspirates from Distant Metastatic Sites

Journal of thoracic oncology, 2008-01, Vol.3 (1), p.18-22

2008

Volltextzugriff (PDF)

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2017-09, Vol.12 (9), p.1357-1367

2017

Volltextzugriff (PDF)

BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience

Journal of thoracic oncology, 2019-03, Vol.14 (3), p.e57-e59

2019

Volltextzugriff (PDF)

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation

Journal of thoracic oncology, 2016-07, Vol.11 (7), p.1051-1063

2016

Volltextzugriff (PDF)

Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience

Lung cancer (Amsterdam, Netherlands), 2020-11, Vol.149, p.5-9

2020

Volltextzugriff (PDF)

Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience

Lung cancer (Amsterdam, Netherlands), 2022-12, Vol.174, p.91-96

2022

Volltextzugriff (PDF)

Clinical significance of ROS1 5’ deletions in non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2019-09, Vol.135, p.88-91

2019

Volltextzugriff (PDF)

Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan

Lung cancer (Amsterdam, Netherlands), 2014-10, Vol.86 (1), p.91-95

2014

Volltextzugriff (PDF)

1 – 25 von 65

Suche als RSS-Feed

Aktive Filter

ThemaRespiratory System

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(65)

Sprache

Englisch
(65)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(65)
Science & Technology
(65)
Oncology
(60)
Humans
(49)
Lung Neoplasms - Drug Therapy
(26)
Male
(26)
Lung Neoplasms - Pathology
(24)
Middle Aged
(24)
Female
(23)
Aged
(22)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(21)
Carcinoma, Non-Small-Cell Lung - Pathology
(19)
Biological And Medical Sciences
(17)
Medical Sciences
(17)
Hematology, Oncology And Palliative Medicine
(16)
Pulmonary/respiratory
(16)
Nsclc
(15)
Adult
(14)
Lung Neoplasms - Genetics
(14)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC

Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect

Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer

Current Status of Second-Line Treatment and Novel Therapies for Small Cell Lung Cancer

Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer

Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients

Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors

Thoracic myopericytoma in an older adult, rare but possible: A case report

ALK Rearrangement Testing by FISH Analysis in Non–Small-Cell Lung Cancer Patients: Results of the First Italian External Quality Assurance Scheme

Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis

Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database

ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data

Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer

Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical Issue

Second-Line Treatment of Advanced Non-small Cell Lung Cancer

Comparison Between Epidermal Growth Factor Receptor (EGFR) Gene Expression in Primary Non-small Cell Lung Cancer (NSCLC) and in Fine-Needle Aspirates from Distant Metastatic Sites

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation

Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience

Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience

Clinical significance of ROS1 5’ deletions in non-small cell lung cancer

Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan

Aktive Filter

Suchergebnisse filtern